Safety-and-effectiveness Clinical Evaluation of Nanosecond-pulse Ablation for Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT06039722

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Shenzhen Pulsecare Medical Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT06039722
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06039722. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-03 (actual); primary completion 2024-08-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety-and-effectiveness Clinical Evaluation of Nanosecond-pulse Ablation for Atrial Fibrillation
Acronym
SCENA-AF
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
Pulse ablation catheter
Lead sponsor
Shenzhen Pulsecare Medical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06039722
Content hash
162b7da4605a77630c2b3dbb8b36665de247f833ddd525d226549cdc44f2b3ce